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METHODS: This retrospective cohort analysis utilized claims from a large national
health plan. Includedweremembers aged 65-89 years, with continuous enrollment
between Jan-2008 and Dec-2009. Patients with T2DM (cases) were propensity
matched 1:1 with non-diabetes patients (controls) by age, gender, ethnicity, geo-
graphic location, low-income status, and plan type. To assess burden of illness,
all-cause health care costs for 2009 were calculated as the sum of all medical and
pharmacy claims (based on ICD-9-CM and GPI codes), and were compared descrip-
tively for cases and controls. In addition, costs directly attributable to diabeteswere
evaluated for the case cohort (based on ICD-9-CM 250.xx and prescriptions for
anti-hyperglycemic agents). RESULTS: The analysis included 179,203 cases and
matched controls. There were no significant differences at baseline between co-
horts with respect to matched variables, however, cases had a significantly higher
mean (SD) Deyo-Charlson Comorbidity Index compared to controls (2.47 versus
0.77 respectively; p0.0001). Mean (SD) all-cause healthcare costs per patient per
year were significantly higher for cases versus controls for in-patient hospitaliza-
tion ($1,120$4,425 vs. $712$3,230), outpatient visits ($5,475$15,640 vs.
$3,620$11,149), office visits ($1,666$3,652 vs. $1,358$3,492), ER visits
($288$868 vs. $219$759), pharmacy costs ($2,195$2,807 vs. $1,342$2,438) and
total healthcare costs ($10,40619,959 vs. $6,993$14,836) respectively, all
p0.0001. The mean diabetes attributable total healthcare cost for the case cohort
was $3,588$9,270 per patient per year. CONCLUSIONS: All cause healthcare costs
were significantly higher for patients with T2DM than for matched controls, high-
lighting the serious burden of illness in this Medicare Advantage population.
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OBJECTIVES: Cushing’s disease (CD), a rare pituitary disorder, is associated with
significant morbidity and mortality, but the economic impact is unknown. This
study assessed the annual healthcare costs and utilization of CD patients.
METHODS: Administrative claims from 2004-2008 of a large population with com-
mercial or Medicare-supplemental insurance in the USwere analyzed. CD patients
were those with medical claims for Cushing’s syndrome (ICD-9-CM: 255.0) and
either benign pituitary adenoma (227.3) or hypophysectomy (07.6). Each CD patient
was age- and gender-matched to four patients with non-functioning pituitary ad-
enoma (NFPA) and ten population controls (PC). NFPA was identified as benign
pituitary adenoma without Cushing’s syndrome, acromegaly (253.0) or hyperpro-
lactinemia (253.1). Comorbid conditions and annual direct healthcare costs were
compared between cohorts by calendar year. RESULTS:The study identified 877 CD
patients (79% female; average age 43 years). Hypertension (43% [CD] vs. 24% [NFPA]
vs. 17% [PC]), diabetes (29% vs. 13% vs. 7%) and hyperlipidemia (27% vs. 21% vs. 14%)
were the most common comorbidities in CD patients and more prevalent than in
NFPApatients and PC (all p0.05). CD patients had significantly higher total health-
care costs than NFPA patients and PC in 2004-2008; the difference between cohorts
increased over time. In 2008, average healthcare costs were $26,440 among CD
patients, compared to $13,708 in NFPA patients and $5,954 in PC (both p0.05).
Approximately one-third of total costs among CD patients were attributable to
CD-related services. CD patients were more likely to have inpatient admissions
(20.7% vs. 15.8% [NFPA] vs. 7.1% [PC], both p0.01), had more frequent outpatient
hospital visits (6.5 vs. 3.8 vs. 1.8, both p0.01), and receivedmoremedications than
NFPA patients and PC (means: 10.0 vs. 7.4 vs. 4.7, both p0.01). CONCLUSIONS: CD
patients had more comorbidities than NFPA patients and PC, and incurred signif-
icantly higher annual healthcare costs.
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OBJECTIVES: Diabetes is a chronic disease that requires continuing care to reduce
the risk of long-term complications. In this sense it is important tomaintain a good
therapeutic arsenal providing good treatment to mantain type 2 diabetes (T2DM)
and hypertension under control, preventing complications. We decided to assess
the costs of the HIPERDIA program with medication provided by the government
for a future cost-effectiveness research. METHODS: HIPERDIA is a program for
monitoring hypertensive and diabetic patients under care in the public healthcare
system. Based on that database, we searched the number of patients under treat-
ment from 2005 to 2010 and also the number of doses of the drugs (glibenclamide
and metformin) available to control T2DM (Datasus/Hiperdia). Also, we looked at
the Brazilian price database (Banco de Preços) the minimum and the maximum
price paid by the government for those drugs to calculate their total costs in the
program. RESULTS: From 2002 to 2010, we found a total of 1,067,754 patients using
glibenclamide 5 mg and 662,519 patients under metformin 850 mg, however it was
not clear the number of patients taking both. The average dailydosewas 1.79 tablet
for glibenclamide and 1.74 for metformin. In the price database from the govern-
ment, we found that the average price paid for glibenclamide was R$ 0.008/daily
unit (ranging from R$ 0.007 to 0.04) and for metformin R$ 0.026/daily unit (ranging
from R$ 0.023 to 0.098). From January 2009 to August 2010 the total cost of this
programwith these 2 drugs reached R$ 1,567,145 and our projections showed that,
since 2002, the government spent about R$ 9 million. CONCLUSIONS: Generics
generated a huge price pressure for those drugs in Brazil and with this scenario it
seems to be difficult to predict the plans to update the drug list to provide more
effective treatments for this population.
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OBJECTIVES: This project presents an analysis of IT processes on variations of
prescribing patterns for patients diagnosedwith diabetes type II, following the first
study on electronic billing and its association with diabetic drug prescribing
(Huttin/Wong,2010).METHODS:A sample of 610 patients is extracted from the CDC
physician survey.IT processes include electronic medical records (EMR), with or
without patient demographics, computerized orders for Rx, tests, lab results, notes
from nurses and physicians, public health reporting. Several hierarchical cluster-
ing methods are tested to identify various stages of IT processes and the impact of
IT is analyzed with non parametric tests (analysis of variance) on prescribing
patterns. RESULTS: Two HB clustering methods (average method and ward) iden-
tify three clusters representing different stages of IT processes: physicians using no
IT at all (80.76%) and two levels of IT operations in practices (cluster 2: 17.33 %;
cluster 3: 1.91%). The dendogram with the AL method presents clearer separation
than the dendogram with the ward method. Variations in drug prescribing is sig-
nificant between clusters, using the scoring savage test:21 for cluster 1, 16.85 for
cluster 2, 4.4 for cluster 3 (P value 0.01). The analysis on new drugs does not show
different prescribing patterns; however, the number of injectables (insulin) per
patient is significantly higher in cluster 2 than 1 (0.51 verus 0.39). Different patterns
of IT processes are also identified within cluster 2 and other clustering methods
among grouping and similarity computations (e.g. Shusaku et als,2004)are tested to
analyze the propagation of IT processes among the practices of this dataset (gen-
eralisation tested with a similarity matrix). CONCLUSIONS: This project can be
used for analysis and management of IT processes inside clinical systems and
control for their effects on physician prescribing behaviours.Results confirm that in
addition to ebilling, different patterns of IT processes have an impact on treatment
regimens (especially affecting insulin or insulin/OAD combinations). This can com-
plement Koro et als study (2004).
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OBJECTIVES: Insulin and other diabetes treatments are generally considered cost
effective treatment options as they reduce the incidence of complications, increase
life expectancy and improve quality of life. This paper quantifies in a new model
the life years saved in the Chinese diabetic population between 2000 and 2010 due
to sales of Novo Nordisk insulin.METHODS: The CORE diabetes model was used to
make projections of long-term survival rates for peoplewith type 2 diabetes treated
with defined therapies; modern insulin monotherapy (MI Mono), Modern Insulin
combined with Oral Anti Diabetics (OAD), human insulin combined with OAD (HI
OAD) and human insulin monotherapy (HI Mono). In the human insulin scenarios,
the base case cohort characteristics were based on the Chinese DiabCare data for
1998 (mean age 56.71 years, 58% male, duration of diabetes 7 years, HbA1c 8.81%).
The modern insulin scenarios (introduced around 2005) are based on cohort char-
acteristics observed in the Chinese PRESENT study (mean age 57.21 years, 51%
male, duration of diabetes 6 years, HbA1c 7.93%). Treatment effects in the four
interventions modelled; MI Mono, MI OAD, HI OAD and HI Mono relied on pub-
lished sources (HbA1c;1%,1.82%,1.2% and 0.7% respectively). The annual size
of the population treated was calculated using annual Novo Nordisk sales and
average daily insulin dosage as observed in the DiabCare China study. This process
was then repeated for each year from 2000 to 2010 making it possible to cumulate
the number of life years saved. RESULTS: The undiscounted life expectancy for the
4 different baseline cohortsmodelled in the CORE diabetesmodel was improved by
2.9, 2.7, 2.2, 1.7 forMIOAD,MIMono, HI OAD,HIMono respectively.CONCLUSIONS:
The cumulated undiscounted life years saved between 2000 and 2010 was esti-
mated at 136.198.66 due to treatment with Novo Nordisk insulin in China.
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OBJECTIVES: Exenatide and liraglutide are the two therapeutic options in the GLP-1
anti-diabetic medication class, to improve glycemic control in adults with type 2
diabetes (T2D). This study evaluated patient and prescriber characteristics, treat-
ment patterns, average daily dose (ADD), and glycemic control of patients initiating
GLP-1 medications in Germany. METHODS: The LifeLink™ EMR-EU database con-
tains records for over 15 million German patients and 3,000 physicians. The cohort
included patients who initiated exenatide or liraglutide during the index period
(01/01/2009 - 04/30/2010). Patients also had 180 days history, pre-index; 90-540
days follow-up, post-index; and a T2D diagnosis (ICD-10 E10-E14), pre-index. Uni-
variate tests were conducted at .05. RESULTS: The cohort included 692 patients
(exenatide 292, liraglutide 400): mean (SD) age 59 (10) years, 59%male. Diabetolo-
gists prescribed liraglutidemore frequently than exenatide (65% vs. 35%) compared
to non-diabetologists (51% vs. 49 %). Choice of GLP-1 was not associated with pa-
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